+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer



Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer



Tuberkuloz Ve Toraks 63(2): 71-77



Vascular endothelial growth factor (VEGF) and Angiopoietin-2 (Ang-2) are major angiogenic mediators in neovascularization process. In current literature both biomarkers are discussed separately and only for non-small cell lung cancer (NSCLC). So in this study we aimed to examine them together for both cell types NSCLC and small cell lung cancer (SCLC). 100 patients with lung cancer were enrolled to this single center study. 87 of patients were diagnosed with NSCLC including 28 adenocarcinomas and 59 squamous cell cancers and 13 were SCLC. Results were compared with 30 healthy volunteers. Pre-treatment serum VEGF and Ang-2 levels were measured by using ELISA method. While serum Ang-2 levels were higher in patients than healthy controls (23395 pg/mL vs. 4025 pg/mL, p< 0.001), VEGF levels didn't differ (2308 pg/mL vs. 2433 pg/mL, p> 0.05). There was no difference between cases with SCLC and NSCLC in terms of Ang-2. But serum VEGF values were significantly lower in SCLC than NSCLC and control groups. None of these mediators were correlated with cell type, tumor size, TNM staging, performance status and operability. VEGF levels were higher in patients with chronic obstructive pulmonary disease (COPD), but it was not significant. Three cut of values were determined according to sensitivity and specificity by using youden index. They were 8515.73 pg/mL (sensitivity 78%, specificity 76%), 7097 pg/mL (sensitivity 80%, specificity 70%) and 11063.48 pg/mL (sensitivity 76%, specificity 70%). Patients with SCLC had shorter survival time above cut-off values (p> 0.05). VEGF and Ang-2 showed a weak positive correlation (p= 0.1 and r= 0.638). In conclusion, serum VEGF wasn't useful to predict lung cancer, prognosis or cell type. Albeit Ang-2 was higher in patients with lung cancer without any effect on survival. Due to the heterogeneity of the studies done with serum measurement Ang-2 on tumor tissue should be more meaningful.

(PDF emailed within 1 workday: $29.90)

Accession: 058637326

Download citation: RISBibTeXText

PMID: 26167963


Related references

Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. Journal of Rheumatology 37(6): 1121-1128, 2010

Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance. Medicina Clinica 122(6): 201-204, 2004

Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ChemoTherapy 58(6): 426-434, 2013

The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respiratory Medicine 98(7): 632-636, 2004

Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Japanese Journal of Clinical Oncology 40(12): 1147-1153, 2010

Prognostic significance of serum hepatocyte growth factor in patients with renal cell carcinoma In comparison with serum vascular endothelial growth factor. Journal of Urology 165(5 Supplement): 185, 2001

Serum vascular endothelial growth factor and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease. Yonsei Medical Journal 53(2): 369-376, 2012

Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leukemia & Lymphoma 55(3): 558-564, 2014

Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Journal of Thoracic Oncology 3(10): 1119-1126, 2008

Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. Isrn Obstetrics and Gynecology 2012: 245756-245756, 2012

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. British Journal of Surgery 91(10): 1354-1360, 2004

Clinicopathologic significance of hypoxia-inducible factor 1α, p53, and vascular endothelial growth factor expression and preoperative serum vascular endothelial growth factor level in gastric cancer. Journal of Clinical Oncology 26(15_suppl): 4576-4576, 2016

Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 37(2): 145-150, 2008

Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for non-small cell lung cancer. Medical Science Monitor 10(6): Br157-Br165, 2004

Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients. European Review for Medical and Pharmacological Sciences 17(21): 2929-2932, 2014